We, therefore, hypothesize that physicians in the present study might have increased ESA doses in cancer patients in an effort to achieve the target Hb value, based on the guidelines for anemia management in dialysis patients.19, 20. This evidence concerns the gene GSTM1 and anemia (phenotype).